| Literature DB >> 25734785 |
Jana Holmar1, Fredrik Uhlin2,3, Anders Fernström3, Merike Luman4,5, Joachim Jankowski6, Ivo Fridolin7.
Abstract
Survival among hemodialysis patients is disturbingly low, partly because vascular calcification (VC) and cardiovascular disease are highly prevalent. Elevated serum phosphorus (P) and calcium (Ca) levels play an essential role in the formation of VC events. The purpose of the current study was to reveal optical monitoring possibilities of serum P and Ca values during dialysis. Twenty-eight patients from Tallinn (Estonia) and Linköping (Sweden) were included in the study. The serum levels of Ca and P on the basis of optical information, i.e., absorbance and fluorescence of the spent dialysate (optical method) were assessed. Obtained levels were compared in means and SD. The mean serum level of Ca was 2.54 ± 0.21 and 2.53 ± 0.19 mmol/L; P levels varied between 1.08 ± 0.51 and 1.08 ± 0.48 mmol/L, measured in the laboratory and estimated by the optical method respectively. The levels achieved were not significantly different (p = 0.5). The Bland-Altman 95% limits of agreement between the two methods varied from -0.19 to 0.19 for Ca and from -0.37 to 0.37 in the case of P. In conclusion, optical monitoring of the spent dialysate for assessing the serum levels of Ca and P during dialysis seems to be feasible and could offer valuable and continuous information to medical staff.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25734785 PMCID: PMC4379520 DOI: 10.3390/toxins7030719
Source DB: PubMed Journal: Toxins (Basel) ISSN: 2072-6651 Impact factor: 4.546
Figure 1Examples of fluorescence spectra of spent dialysate taken at the start (10 min) and at the end (240 min) of the dialysis procedure. Excitation (EX) = 220–500 nm, Emission (EM) = 220–500 nm.
Figure 2Examples of absorbance spectra of spent dialysate samples taken at the start and at the end of the dialysis over a wavelength range 190–380 nm.
Serum total calcium and phosphorous concentration values estimated by different methods.
| Min | Max | Mean | SD | N | R | R2 | St. Error of Estimate | |
|---|---|---|---|---|---|---|---|---|
|
| 2.15 | 2.95 | 2.54 | 0.21 | 83 | |||
|
| 2.22 | 2.95 | 2.53 | 0.19 | 83 | 0.90 | 0.81 | 0.093 |
|
| 0.42 | 2.85 | 1.08 | 0.51 | 142 | |||
|
| 0.38 | 2.76 | 1.08 | 0.48 | 142 | 0.93 | 0.87 | 0.182 |
Values from the laboratory and estimated by the optical method were compared using paired Student t-test; the values are not statistically different (p = 0.5).
Figure 3Goodness of fit of the multiple linear regression models for estimating the serum concentration of (a) Ca and (b) P.
Figure 4Bland-Altman plots. The individual differences between the levels of (a) Ca and (b) P concentrations from the laboratory and those estimated by the optical method plotted against the mean value of levels from the lab and the optical method.
Data of the studied patients.
| Patient | Kidney Disease | Age | Gender | BMI | Time on HD (months) | Dialyzer Type and Membrane Area | Dialysis Access | Procedure Type (HD/HDF) |
|---|---|---|---|---|---|---|---|---|
| 1 | Polycystic kidney disease | 83 | M | 23.5 | 109 | FX80-1.8 m2 | a/v fistula | HD and HDF |
| 2 | Atherosclerosis | 57 | M | 22.5 | 32 | FX80-1.8 m2 | a/v fistula | HD and HDF |
| 3 | Diabetic nephropathy | 85 | M | 18.7 | 36 | FX80-1.8 m2 | a/v fistula | HD and HDF |
| 4 | Hypertensive renal disease | 81 | F | 34.6 | 12 | FX80-1.8 m2 | graft | HD and HDF |
| 5 | Diabetic nephropathy | 84 | M | 24.4 | 29 | FX80-1.8 m2 | a/v fistula | HD and HDF |
| 6 | Polycystic kidney disease | 49 | M | 16.7 | 45 | FX80-1.8 m2 | a/v fistula | HD and HDF |
| 7 | Diabetic nephropathy | 76 | M | 29.0 | 32 | FX80-1.8 m2 | a/v fistula | HD and HDF |
| 8 | Atherosclerosis | 73 | M | 33.2 | 24 | FX80-1.8 m2 | a/v fistula | HD and HDF |
| 9 | Glomerulo-nephritis | 69 | F | 27.1 | 47 | FX10-1.8 m2 | a/v fistula | HD |
| 10 | Tubulointerstitial nephritis | 62 | F | 20.3 | 7 | FX10-1.8 m2 | a/v fistula | HD |
| 11 | Diabetic nephropathy | 60 | F | 26.4 | 24 | FX80-1.8 m2 | graft | HDF |
| 12 | Polycystic kidney disease | 68 | M | 27.8 | 96 | FX80-1.8 m2 | graft | HDF |
| 13 | Polycystic kidney disease | 43 | M | 23.9 | 16 | FX80-1.8 m2 | graft | HDF |
| 14 | Tubulointerstitial nephritis | 60 | M | 27.1 | 26 | FX80-1.8 m2 | a/v fistula | HDF |
| 15 | Hypertensive renal disease | 48 | M | 27.8 | 8 | FX10-1.8 m2 | a/v fistula | HD |
| 16 | Hypertensive renal disease | 59 | M | 26.9 | 28 | FX80-1.8 m2 | a/v fistula | HDF |
| 17 | Myeloma | 56 | F | 30.5 | 28 | FX80-1.8 m2 | graft | HDF |
| 18 | Myeloma | 58 | M | 25.6 | 29 | FX80-1.8 m2 | a/v fistula | HDF |
| 19 | Diabetic nephropathy | 74 | F | 27.0 | 37 | FX10-1.8 m2 | a/v fistula | HD |
| 20 | Polycystic kidney disease | 46 | M | 22.6 | 42 | FX80-1.8 m2 | graft | HDF |
| 21 | Myeloma | 58 | F | 30.5 | 53 | FX100-1.8 m2 | graft | HDF |
| 22 | Tubulointerstitial nephritis | 43 | F | 19.0 | 23 | FX80-1.8 m2 | a/v fistula | HDF |
| 23 | Hypertensive renal disease | 73 | M | 27.1 | 44 | FX80-1.8 m2 | permanent dialysis catheter | HDF |
| 24 | Tubulointerstitial nephritis | 56 | M | 23.9 | 52 | FX80-1.8 m2 | a/v fistula | HDF |
| 25 | Diabetic nephropathy | 58 | M | 37.6 | 36 | FX100-1.8 m2 | a/v fistula | HDF |
| 26 | Hypertensive renal disease | 80 | M | 20.3 | 81 | FX10-1.8 m2 | a/v fistula | HD |
| 27 | Myeloma | 60 | M | 25.3 | 55 | FX100-1.8 m2 | a/v fistula | HDF |
| 28 | Tubulointerstitial nephritis | 64 | F | 23.0 | 28 | FX80-1.8 m2 | a/v fistula | HD |